Grant Award Details
- To develop an allogeneic, enucleated stem cell-based oncolytic therapy for breast cancer (CA-oVSVIFNb)
Grant Application Details
- Development of a novel stem-cell based carrier for intravenous delivery of oncolytic viruses
Develop a stem cell-based platform that safely and efficiently delivers viruses that specifically kill tumor cells and restore immune activity in patients with advanced cancer.
Overcome the inherent limitations that prevent efficient intravenous delivery of tumor killing viruses to metastatic tumors.
Major Proposed Activities
- Compare the relative efficacy of native or cargocyte-delivered oVSV-GFP∆M51-GFP to home to, and infect, metastatic breast cancer cells.
- Compare the relative efficacy of native or cargocyte-delivered oVSV∆M51-GFP to exit tumor blood vessels and escape neutralizing antibodies.
- Compare the relative efficacy of native versus cargocyte -delivered oVSV∆M51-GFP to specifically infect tumor tissue versus nonmalignant tissue
- Compare the relative efficacy of native versus cargocyte-delivered oVSV∆M51-IFNβ to promote objective breast tumor regression and reduce overall metastatic load
- Compare the relative efficacy of native versus cargocyte-delivered oVSV∆M51-IFNβ to break cancer-induced immune tolerance
If successful, this proposal will provide the necessary data that will enable the design of clinical trials for improved delivery of tumor killing viruses for the treatment of nonresectable, recurrent, or metastatic solid tumors using stem cell-derived biocarriers.